ATE204881T1 - Chimäre lipidkörper-pro-grf analoge mit erhöheter biologischer potenz - Google Patents

Chimäre lipidkörper-pro-grf analoge mit erhöheter biologischer potenz

Info

Publication number
ATE204881T1
ATE204881T1 AT96914826T AT96914826T ATE204881T1 AT E204881 T1 ATE204881 T1 AT E204881T1 AT 96914826 T AT96914826 T AT 96914826T AT 96914826 T AT96914826 T AT 96914826T AT E204881 T1 ATE204881 T1 AT E204881T1
Authority
AT
Austria
Prior art keywords
grf
pro
increased biological
biological potency
lipid body
Prior art date
Application number
AT96914826T
Other languages
English (en)
Inventor
Michel Ibea
Thierry Abribat
Paul Brazeau
Original Assignee
Theratechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27036979&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE204881(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Theratechnologies Inc filed Critical Theratechnologies Inc
Application granted granted Critical
Publication of ATE204881T1 publication Critical patent/ATE204881T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/12—Growth hormone, growth factor other than t-cell or b-cell growth factor, and growth hormone releasing factor; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
AT96914826T 1995-05-26 1996-05-22 Chimäre lipidkörper-pro-grf analoge mit erhöheter biologischer potenz ATE204881T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45306795A 1995-05-26 1995-05-26
US65164596A 1996-05-22 1996-05-22
PCT/CA1996/000327 WO1996037514A1 (en) 1995-05-26 1996-05-22 Chimeric fatty body-pro-grf analogs with increased biological potency

Publications (1)

Publication Number Publication Date
ATE204881T1 true ATE204881T1 (de) 2001-09-15

Family

ID=27036979

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96914826T ATE204881T1 (de) 1995-05-26 1996-05-22 Chimäre lipidkörper-pro-grf analoge mit erhöheter biologischer potenz

Country Status (13)

Country Link
US (2) US5939386A (de)
EP (1) EP0828758B1 (de)
JP (1) JP3576170B2 (de)
KR (1) KR100543190B1 (de)
AT (1) ATE204881T1 (de)
AU (1) AU697119B2 (de)
BR (2) BRPI9608799B8 (de)
CA (1) CA2222068C (de)
DE (1) DE69614849T2 (de)
DK (1) DK0828758T3 (de)
ES (1) ES2163020T3 (de)
PT (1) PT828758E (de)
WO (1) WO1996037514A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020311A (en) * 1995-05-26 2000-02-01 Theratechnologies, Inc. GRF analogs with increased biological potency
US6458764B1 (en) * 1995-05-26 2002-10-01 Theratechnologies Inc. GRF analogs with increased biological potency
US6121416A (en) * 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US6696063B1 (en) * 1998-12-30 2004-02-24 Applied Research Systems Ars Holding N.V. Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy
AU762351B2 (en) 1999-01-06 2003-06-26 Genentech Inc. Insulin-like growth factor (IGF) I mutant variants
JP2000350590A (ja) * 1999-04-12 2000-12-19 Pfizer Prod Inc 成長ホルモン及び成長ホルモン放出ホルモン組成物
US6759393B1 (en) 1999-04-12 2004-07-06 Pfizer Inc. Growth hormone and growth hormone releasing hormone compositions
AU2001263215A1 (en) 2000-05-16 2001-11-26 Genentech Inc. Method for treating cartilage disorders
CN1454214A (zh) * 2000-08-02 2003-11-05 赛莱技术公司 具有增高功效的修饰生物肽
EP1205551A1 (de) * 2000-11-09 2002-05-15 Pfizer Products Inc. Wachstumshormon- (GH) und Wachstumshormon-freisetzenden Hormon (GHRH) enthaltende Zusammensetzungen
FR2851461B1 (fr) * 2003-02-21 2007-04-20 Seppic Sa Utilisation de n-octanoyl aminoacides comme actif cosmetique et pharmaceutique amincissant
AU2003229222B2 (en) * 2003-05-29 2009-11-12 Theratechnologies Inc. GRF analog compositions and their use
DK2274978T3 (en) 2003-09-12 2015-06-15 Ipsen Biopharmaceuticals Inc Methods of treating an insulin-like growth factor-I (IGF-I) deficiency
US7893025B2 (en) * 2003-10-20 2011-02-22 Theratechnolgies Inc. Use of growth hormone releasing factor analogs in treating patients suffering from wasting
US8889632B2 (en) 2007-01-31 2014-11-18 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
EP2508531B1 (de) 2007-03-28 2016-10-19 President and Fellows of Harvard College Geheftete Polypeptide
US20100267635A1 (en) * 2009-04-20 2010-10-21 Theratechonolgies Inc. Use of protease inhibitors and grf molecules in combination therapy
EP2421548A4 (de) * 2009-04-20 2012-09-26 Theratechnologies Inc Verwendung von (hexenoyl-trans-3)hgrf(l-44)nh2 und simvastatin in einer kombinationstherapie
SI2603600T1 (sl) 2010-08-13 2019-04-30 Aileron Therapeutics, Inc. Peptidomimetični makrocikli
EP2616095A4 (de) * 2010-09-16 2014-03-19 Univ Miami Wundheilungsbeschleunigung durch ein wachstumshormon-freisetzendes hormon und seine agonisten
BR112013027150A2 (pt) 2011-04-21 2017-06-06 Theratechnologies Inc thera
TW201806968A (zh) 2011-10-18 2018-03-01 艾利倫治療公司 擬肽巨環化合物
KR102112373B1 (ko) 2012-02-15 2020-05-18 에일러론 테라퓨틱스 인코포레이티드 펩티드모방체 마크로사이클
HK1205454A1 (en) 2012-02-15 2015-12-18 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
CN102702343A (zh) * 2012-06-14 2012-10-03 吉尔生化（上海）有限公司 一种固相合成替莫瑞林的方法
WO2013190520A2 (en) 2012-06-22 2013-12-27 The General Hospital Corporation Gh-releasing agents in the treatment of vascular stenosis and associated conditions
WO2014071241A1 (en) 2012-11-01 2014-05-08 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
US8871713B2 (en) 2013-03-01 2014-10-28 Theratechnologies Inc. Formulations of growth hormone releasing factor (GRF) molecules with improved stability
BR112017005598A2 (pt) 2014-09-24 2017-12-12 Aileron Therapeutics Inc macrociclos peptidomiméticos e usos dos mesmos
WO2016154058A1 (en) 2015-03-20 2016-09-29 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
MX2018012716A (es) 2016-04-19 2019-02-11 Griffon Pharmaceuticals Inc Peptidos bioactivos pegilados y usos de los mismos.
EP4608388A1 (de) * 2022-10-25 2025-09-03 Starrock Pharma Inc. Kombinatorische und rotierende kombinatorische therapien für adipositas und andere erkrankungen

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4622312A (en) * 1984-09-24 1986-11-11 Hoffmann-La Roche Inc. Growth hormone releasing factor analogs
CA1271600A (en) * 1985-01-07 1990-07-10 David Howard Coy Growth hormone-releasing peptides and method of treating mammals therewith
US4870054A (en) * 1985-09-27 1989-09-26 Recker Robert R Treatment for osteoporosis using GRF or a biologically active analog thereof
DE3742633A1 (de) * 1987-12-16 1989-06-29 Hoechst Ag Peptide mit beeinflussender wirkung auf die hypophyse von saeugern
IL86102A (en) * 1987-05-11 1994-04-12 Univ Tulane Alkylated growth hormone-releasing peptides and use thereof
FR2622455B1 (fr) * 1987-11-04 1991-07-12 Agronomique Inst Nat Rech Application du facteur de stimulation de la secretion de l'hormone de croissance humaine, de ses fragments actifs et des analogues correspondants, pour augmenter la production laitiere et le poids des nouveau-nes chez les mammiferes
US5065748A (en) * 1989-11-14 1991-11-19 University Of South Florida Method of diagnosing growth hormone disorders employing somatostatin and growth hormone releasing hormone
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
ZA922746B (en) * 1991-04-26 1992-12-30 Lilly Co Eli Superactive grf analogs

Also Published As

Publication number Publication date
WO1996037514A1 (en) 1996-11-28
MX9709098A (es) 1998-06-30
PT828758E (pt) 2002-02-28
BR9608799B1 (pt) 2009-12-01
ES2163020T3 (es) 2002-01-16
KR100543190B1 (ko) 2006-06-23
CA2222068A1 (en) 1996-11-28
JPH11505807A (ja) 1999-05-25
US5939386A (en) 1999-08-17
CA2222068C (en) 2007-04-10
EP0828758B1 (de) 2001-08-29
AU697119B2 (en) 1998-09-24
DE69614849D1 (de) 2001-10-04
DK0828758T3 (da) 2002-01-07
JP3576170B2 (ja) 2004-10-13
BRPI9608799B8 (pt) 2019-11-05
BR9608799A (pt) 1999-12-07
DE69614849T2 (de) 2002-05-16
US5861379A (en) 1999-01-19
KR19990021938A (ko) 1999-03-25
EP0828758A1 (de) 1998-03-18
AU5683396A (en) 1996-12-11

Similar Documents

Publication Publication Date Title
DE69614849D1 (de) Chimäre lipidkörper-pro-grf analoge mit erhöheter biologischer potenz
ATE311453T1 (de) Grf-analoge mit erhöhter biologischer potenz
ATE494902T1 (de) Ein huhn gnrh-ii analog zur verwendung in der reduktion des tumorzellwachstums
GB8922026D0 (en) Novel anti-viral and cytotoxic agent
ES2060158T3 (es) Uso de alcoholes alifaticos c-22 a c-26 en el tratamiento de enfermedades de la piel inflamatorias y viricas.
ATE76296T1 (de) Pharmazeutische zusammensetzung zur behandlung von akuter myocardischer ischaemie.
RU93005051A (ru) Способ получения катионных кристаллов гр или производных гр, катионные кристаллы человеческого гр или производных человеческого гр, фармацевтические препараты, использование процесса кристаллизации
FI842166L (fi) Bukspottskoertelns grf hos maenniskan.
DE69025920D1 (de) Glykosaminoglykan-modifiertes Protein, Verfahren zu dessen Herstellung und pharmazeutische Zubereitungen, die es enthalten
FR2591485B1 (fr) Compositions stabilisees contenant l'activateur du plasminogene du tissu humain.
HK16492A (en) Pharmaceutical compositions of somatostatin analogues
EP0203649A3 (en) Pharmaceutic composition based on diphoshonates for the treatment of the arthrosis
DK193887D0 (da) Fysiologisk aktivt peptid
SE8008415L (sv) Cyklisk analog for fagocytosstimulerande naturpeptid, dvs treonyl-cyklo-(-n-lysyl-prolyl-arginyl-)
GR3005612T3 (de)
CY1105683T1 (el) Ενεργο συζυγες ακανθοχοιρικης πρωτεϊνης, μεθοδος για την παρασκευη και χρηση αυτου
ES2002083A6 (es) Un metodo para preparar derivados de piroglutamida
DE2547721A1 (de) Biologisch aktive amide
ATE25708T1 (de) Biologisch aktive konjugate, ihre herstellung und ihre anwendung.
GR3029319T3 (en) Use of tri(n-butyl) phosphate at low pH in solutions of biologically active proteins for enhanced virucidal activity
IL85029A (en) Microcrystalline cis diammineplatinum(ii)complex of 1,1-cyclobutanedicarboxylic acid,its preparation and cytostatic pharmaceutical compositions containing it
CA2073554A1 (en) Water-soluble composition for sustained-release
Vinson et al. α-MSH analogues and adrenal zona glomerulosa function
AU4882693A (en) Supply of biologically beneficial substances to ruminant animals
IL84758A0 (en) Peptides stimulating the release of pituitary growth hormone in fish and amphibians,and pharmaceutical compositions containing them